Clinical Trials
57 trialsKANDLELIT-001
Merck Sharp & Dohme LLC
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
MOONRAY-01
Eli Lilly and Company
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
ARC-25
Arcus Biosciences, Inc.
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
MK-4280-001
Merck Sharp & Dohme LLC
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Hansoh BioMedical R&D Company
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
KEYNOTE-651
Merck Sharp & Dohme LLC
IVY
Eli Lilly and Company
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Hoffmann-La Roche
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
FABLOx
Celgene
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
mAbxience Research S.L.
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
GlaxoSmithKline
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Traws Pharma, Inc.